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Supplementary Figures
Supplementary Figure S1 . Sensitivity of DHPLC assay. Supplementary Figure S1 . Sensitivity of DHPLC assay was determined by mixing various quantities of sequence-confirmed mutants with wild-type to make mutant levels of 5%, 10%, 20% and 50%. The detection limit is 5% for each DNMT3A mutant in our assay system. Figure S5A . Event-free survival according to class IV gene mutation status in pediatric non-APL patients. Figure S5B . Overall survival according to class IV gene mutation status in pediatric non-APL patients.
